1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Bacterial Pneumonia - Pipeline Review, H2 2016

Bacterial Pneumonia - Pipeline Review, H2 2016

  • December 2016
  • -
  • Global Markets Direct
  • -
  • 212 pages

Bacterial Pneumonia - Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Pneumonia – Pipeline Review, H2 2016, provides an overview of the Bacterial Pneumonia (Infectious Disease) pipeline landscape.

Bacterial pneumonia is an infection in one or both lungs. The bacteria cause the lung’s air sacs (alveoli) to become inflamed and engorged with pus, fluid, and cellular debris. This often impairs the body’s ability to exchange oxygen and carbon dioxide. Predisposing factors are age, long-term users of immunosuppressant drugs, chronic obstructive pulmonary disease (COPD) patients who use inhaled corticosteroids for lengthy periods and smokers. Symptoms include cough with yellow, green, or blood-tinged mucus, headache, muscle pain, breathlessness or rapid breathing, lethargy and confusion.


Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Bacterial Pneumonia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bacterial Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 8, 13, 2, 30, 12 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 9 and 6 molecules, respectively.

Bacterial Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Bacterial Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bacterial Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bacterial Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Pneumonia (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bacterial Pneumonia (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bacterial Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Bacterial Pneumonia - Pipeline Review, H2 2016
Table of Contents
Table of Contents 2
Introduction 5
Bacterial Pneumonia Overview 6
Therapeutics Development 7
Bacterial Pneumonia - Therapeutics under Development by Companies 9
Bacterial Pneumonia - Therapeutics under Investigation by Universities/Institutes 12
Bacterial Pneumonia - Pipeline Products Glance 13
Bacterial Pneumonia - Products under Development by Companies 17
Bacterial Pneumonia - Products under Investigation by Universities/Institutes 21
Bacterial Pneumonia - Companies Involved in Therapeutics Development 22
Bacterial Pneumonia - Therapeutics Assessment 65
Drug Profiles 75
Bacterial Pneumonia - Dormant Projects 185
Bacterial Pneumonia - Discontinued Products 190
Bacterial Pneumonia - Product Development Milestones 191
Appendix 201

List of Tables
Number of Products under Development for Bacterial Pneumonia, H2 2016 17
Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, H2 2016 18
Number of Products under Development by Companies, H2 2016 19
Number of Products under Development by Companies, H2 2016 (Contd..1) 20
Number of Products under Development by Companies, H2 2016 (Contd..2) 21
Number of Products under Investigation by Universities/Institutes, H2 2016 22
Comparative Analysis by Late Stage Development, H2 2016 23
Comparative Analysis by Clinical Stage Development, H2 2016 24
Comparative Analysis by Early Stage Development, H2 2016 25
Comparative Analysis by Unknown Stage Development, H2 2016 26
Products under Development by Companies, H2 2016 27
Products under Development by Companies, H2 2016 (Contd..1) 28
Products under Development by Companies, H2 2016 (Contd..2) 29
Products under Development by Companies, H2 2016 (Contd..3) 30
Products under Investigation by Universities/Institutes, H2 2016 31
Bacterial Pneumonia - Pipeline by Abera Bioscience AB, H2 2016 32
Bacterial Pneumonia - Pipeline by Actelion Ltd, H2 2016 33
Bacterial Pneumonia - Pipeline by Affinivax Inc, H2 2016 34
Bacterial Pneumonia - Pipeline by Allergan Plc, H2 2016 35
Bacterial Pneumonia - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 36
Bacterial Pneumonia - Pipeline by Arsanis Inc, H2 2016 37
Bacterial Pneumonia - Pipeline by AstraZeneca Plc, H2 2016 38
Bacterial Pneumonia - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 39
Bacterial Pneumonia - Pipeline by Biken Inc, H2 2016 40
Bacterial Pneumonia - Pipeline by ContraFect Corp, H2 2016 41
Bacterial Pneumonia - Pipeline by Crestone Inc, H2 2016 42
Bacterial Pneumonia - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 43
Bacterial Pneumonia - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 44
Bacterial Pneumonia - Pipeline by Double Bond Pharmaceutical International AB, H2 2016 45
Bacterial Pneumonia - Pipeline by Emergent BioSolutions Inc, H2 2016 46
Bacterial Pneumonia - Pipeline by FluGen Inc, H2 2016 47
Bacterial Pneumonia - Pipeline by GlaxoSmithKline Plc, H2 2016 48
Bacterial Pneumonia - Pipeline by ImmunoBiology Ltd, H2 2016 49
Bacterial Pneumonia - Pipeline by Indian Immunologicals Ltd, H2 2016 50
Bacterial Pneumonia - Pipeline by Integrated BioTherapeutics Inc, H2 2016 51
Bacterial Pneumonia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 52
Bacterial Pneumonia - Pipeline by Lascco SA, H2 2016 53
Bacterial Pneumonia - Pipeline by LegoChem Biosciences Inc, H2 2016 54
Bacterial Pneumonia - Pipeline by LG Life Science LTD, H2 2016 55
Bacterial Pneumonia - Pipeline by Liquidia Technologies Inc, H2 2016 56
Bacterial Pneumonia - Pipeline by MedImmune LLC, H2 2016 57
Bacterial Pneumonia - Pipeline by Merck and Co Inc, H2 2016 58
Bacterial Pneumonia - Pipeline by Mucosis BV, H2 2016 59
Bacterial Pneumonia - Pipeline by Noxxon Pharma AG, H2 2016 60
Bacterial Pneumonia - Pipeline by Panacea Biotec Ltd, H2 2016 61
Bacterial Pneumonia - Pipeline by Pfizer Inc, H2 2016 62
Bacterial Pneumonia - Pipeline by Polyphor Ltd, H2 2016 63
Bacterial Pneumonia - Pipeline by Prometheon Pharma LLC, H2 2016 64
Bacterial Pneumonia - Pipeline by Sanofi Pasteur SA, H2 2016 65
Bacterial Pneumonia - Pipeline by Serum Institute of India Ltd, H2 2016 66
Bacterial Pneumonia - Pipeline by Shionogi and Co Ltd, H2 2016 67
Bacterial Pneumonia - Pipeline by SK Chemicals Co Ltd, H2 2016 68
Bacterial Pneumonia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 69
Bacterial Pneumonia - Pipeline by Valneva SE, H2 2016 70
Bacterial Pneumonia - Pipeline by Vaxxilon AG, H2 2016 71
Bacterial Pneumonia - Pipeline by Virometix AG, H2 2016 72
Bacterial Pneumonia - Pipeline by Wellstat Vaccines LLC, H2 2016 73
Bacterial Pneumonia - Pipeline by Wockhardt Ltd, H2 2016 74
Assessment by Monotherapy Products, H2 2016 75
Assessment by Combination Products, H2 2016 76
Number of Products by Stage and Target, H2 2016 78
Number of Products by Stage and Mechanism of Action, H2 2016 80
Number of Products by Stage and Route of Administration, H2 2016 82
Number of Products by Stage and Molecule Type, H2 2016 84
Bacterial Pneumonia - Dormant Projects, H2 2016 195
Bacterial Pneumonia - Dormant Projects (Contd..1), H2 2016 196
Bacterial Pneumonia - Dormant Projects (Contd..2), H2 2016 197
Bacterial Pneumonia - Dormant Projects (Contd..3), H2 2016 198
Bacterial Pneumonia - Dormant Projects (Contd..4), H2 2016 199
Bacterial Pneumonia - Discontinued Products, H2 2016 200

List of Figures
Number of Products under Development for Bacterial Pneumonia, H2 2016 17
Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, H2 2016 18
Number of Products under Development by Companies, H2 2016 19
Number of Products under Investigation by Universities/Institutes, H2 2016 22
Comparative Analysis by Late Stage Development, H2 2016 23
Comparative Analysis by Clinical Stage Development, H2 2016 24
Comparative Analysis by Early Stage Products, H2 2016 25
Assessment by Monotherapy Products, H2 2016 75
Assessment by Combination Products, H2 2016 76
Number of Products by Top 10 Targets, H2 2016 77
Number of Products by Stage and Top 10 Targets, H2 2016 77
Number of Products by Top 10 Mechanism of Actions, H2 2016 79
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 79
Number of Products by Routes of Administration, H2 2016 81
Number of Products by Stage and Routes of Administration, H2 2016 81
Number of Products by Top 10 Molecule Types, H2 2016 83
Number of Products by Stage and Top 10 Molecule Types, H2 2016 83

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N-Formyl ...

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2016

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, ...

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2016

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin ...

Rabies - Pipeline Review, H2 2016

October 2016 $ 2000

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.